- Record: found
- Abstract: not found
- Article: not found
Overall survival and biomarker results from a phase 2 study of MEK1/2 inhibitor binimetinib (MEK162) in patients with advanced NRAS-mutant melanoma
C Van Herpen, SS Agarwala, A Hauschild, R Dummer, C Berking, JT Beck, D SCHADENDORF, GT Gibney, R Jansen, P Queirolo, PA Ascierto, CU Blank, H Nauwelaerts
2014
Read this article at
ScienceOpen
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.